source
- Viatris to acquire Pacira BioSciences for $1.65 billion, expanding its non‑opioid pain portfolioViatris, a maker of generic and branded medicines, announced a cash purchase of commercial‑stage Pacira BioSciences for $1.65 billion. The deal adds Pacira’s non‑opioid pain treatments to Viatris’…
- Ono Pharmaceutical pays Biohaven $80 million for protein degrader as UK pulls Valneva's chikungunya vaccineTokyo-based Ono Pharmaceutical announced it will pay Biohaven $80 million upfront to license a pan‑IgG protein degrader technology. The agreement gives Ono rights to develop the degrader, while Bi…